Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy

Clinical Infectious Diseases

Volumn 57, Issue 5, 2013, Pages 756-764

  Yanik, Elizabeth L ^a   Napravnik, Sonia ^a,b   Cole, Stephen R ^a   Achenbach, Chad J ^c   Gopal, Satish ^b   Olshan, Andrew ^a   Dittmer, Dirk P ^b   Kitahata, Mari M ^d   Mugavero, Michael J ^e   Saag, Michael ^e   Moore, Richard D ^f   Mayer, Kenneth ^g   Mathews, W Christopher ^h   Hunt, Peter W ⁱ   Rodriguez, Benigno ^j   Eron, Joseph J ^b  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e and Clinical Center   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g FENWAY INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

AIDS defining cancer; combination antiretroviral therapy; HIV associated malignancies; non AIDS defining cancer

Indexed keywords

INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGING; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MEN WHO HAVE SEX WITH MEN; MULTIPLE MYELOMA; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PERITONEUM CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SMALL INTESTINE CANCER; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; UTERINE CERVIX CANCER; VIRUS LOAD; WART VIRUS;

AIDS-DEFINING CANCER; COMBINATION ANTIRETROVIRAL THERAPY; HIV-ASSOCIATED MALIGNANCIES; NON-AIDS-DEFINING CANCER;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS; UNITED STATES;

EID: 84881447004     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit369     Document Type: Article

References (30)

1. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-54.
2. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIVinfected population in the United States. J Natl Cancer Inst 2011; 103: 753-62.
3. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-30.
4. Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 2010; 51:957-62.
5. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer 2010; 103:416-22.
6. Pipkin S, Scheer S, Okeigwe I, Schwarcz S, Harris DH, Hessol NA. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: Results of a match between an AIDS and cancer registry. AIDS 2011; 25:463-71.
7. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-36.
8. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol 2009; 10:1152-9.
9. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48:491-9.
10. Chao C, Leyden WA, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS 2012; 26:2223-31.
11. Kitahata MM, Rodriguez B, Haubrich R, et al. Cohort profile: The Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol 2008; 37:948-55.
12. Achenbach CJ, Cole SR, Kitahata MM, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011; 25:691-700.
13. Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800-4.
14. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-72.
15. Petoumenos K, van Leuwen M, Vajdic C, et al. Cancer, immunodeficiency and antiretroviral treatment: Results from the Australian HIV Observational Database (AHOD). HIV Med 2013; 14:77-84.
16. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011; 20:2551-9.
17. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst Monogr 2005; 97:425-32.
18. Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS 2011; 25:1395-403.
19. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224-8.
20. Feller L, Anagnostopoulos C, Wood NH, Bouckaert M, Raubenheimer EJ, Lemmer J. Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: A literature review and case report. J Periodontol 2008; 79:362-8.
21. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012; 54:424-33.
22. Lanoy E, Rosenberg PS, Fily F, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood 2011; 118:44-9.
23. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: Etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009; 23:875-85.
24. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated cancer: Has highly active antiretroviral therapy reduced the incidence or improved the outcome?. J Acquir Immune Defic Syndr 2004; 37: 1563-5.
25. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120-30.
26. Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010; 24:535-43.
27. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22: 1203-11.
28. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndromedefining malignancies. Cancer 2010; 116:5306-15.
29. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-94.
30. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951-60.